Undisclosed Pipeline

About Authera

Authera is a science-driven biotech founded in 2022, building on decades of foundational research in FcRn biology from its academic founders. The company operates a cutting-edge technology platform that integrates biochemical, cellular, and in vivo models to de-risk the development of novel biologics with fine-tuned FcRn interactions. With a lead program in pre-clinical development for severe eye diseases and recent non-dilutive grant funding, Authera is positioned to advance its pipeline while seeking strategic partnerships to explore the broad therapeutic utility of its platform.

About Pathos AI

Pathos AI is an AI-enabled, clinical-stage biotech company founded in 2020 and headquartered in New York. The company's core mission is to address the high failure rate in early-stage oncology drug development by leveraging what it claims is the world's largest multimodal dataset of oncology patient records, combined with a proprietary AI data model. This platform is designed to simulate clinical trial scenarios, identify responsive patient subgroups, and de-risk drug development for both its internal pipeline and biopharma partners. Pathos positions itself not just as a drug developer but as a company building a new, data-driven standard for the entire drug development process in precision oncology.

About Juniper Biosciences

Juniper Biosciences is a private, pre-revenue biotech company developing a pipeline of radiopharmaceutical theranostics. The company leverages a platform that links radioisotopes to high-specificity ligands to enable precise diagnosis and treatment of cancers, aiming to minimize side effects and maximize therapeutic impact. With a team possessing decades of combined experience in the field, Juniper is advancing multiple programs from pre-clinical stages towards the clinic. Its vision is to become a leader in nuclear medicine innovation by improving patient access to novel radiopharmaceuticals.

About IMMvention Therapeutix

IMMvention Therapeutix is a private, preclinical-stage biotech developing small molecule immunotherapies for autoimmune and inflammatory conditions. Operating from the biotech hub of Cambridge, MA, the company is in the early stages of building its pipeline and technology platform. As a pre-revenue entity, its success hinges on advancing its research into clinical development and securing strategic partnerships or funding to validate its approach.

About Soley Therapeutics

Soley Therapeutics, founded in 2016 and based in Cambridge, USA, is a private biotech pioneering a novel drug discovery paradigm. The company's core platform uses living cells under stress as information-rich sensors, applying proprietary imaging and AI to map cellular responses and uncover new therapeutic mechanisms, particularly for hard-to-drug targets like protein-protein interactions. This biology-first approach aims to generate a pipeline of first-in-class small molecule drugs with improved selectivity and safety profiles for complex diseases in oncology and inflammation. Soley is currently in the pre-clinical stage, advancing its platform and initial programs.

About AlphaRose Therapeutics

AlphaRose Therapeutics is an early-stage biotech company building a new model to develop and commercialize genetic treatments for rare diseases at scale. Founded by CEO Casey McPherson following his daughter's diagnosis, the company combines a patient-centric mission with experienced leadership from the legacy of Genzyme. While specific pipeline details are not publicly disclosed, the company's focus is on leveraging undiscovered genetic technologies and a novel commercial approach to tackle the critical gap in treatments for millions of children with rare genetic conditions. Its ambitious vision is to eradicate genetic disease by 2040.

About Aspargo Laboratories

Aspargo Laboratories, founded in 2018 and headquartered in Cambridge, USA, is a private biotech company developing a platform for oral suspension drug reformulation. Its lead asset, ASP-001 (liquid sildenafil), is commercially available in several European countries and has completed clinical trials for an FDA NDA submission. The company's strategy leverages its suspension technology to enhance bioavailability and patient adherence, with a future vision that includes a connected device platform for personalized dosing and data tracking across multiple medications.

About Theravia

Theravia is a private, commercial-stage biopharmaceutical company with a targeted focus on rare and neglected diseases, particularly sickle cell disease. With over 20 years of collective experience from its predecessor entities, the company has established a commercial footprint in over 35 countries, treating more than 15,000 patients. Its strategy centers on in-licensing, developing, and marketing specialized therapies, supported by a partnership-driven model to build its pipeline and expand global access.

About Orbis Medicines

Orbis Medicines is a well-funded, private biotech leveraging its high-throughput nGen platform to unlock oral macrocycle therapeutics, a long-standing challenge in drug discovery. The company has assembled a world-class team and board, secured significant Series A financing, and established key collaborations to advance a pipeline initially focused on creating oral alternatives to injectable biologics. By combining massive DNA-encoded library screening, automated synthesis, and AI-driven analysis, Orbis aims to de-risk and accelerate the development of these promising molecules across multiple therapeutic areas.

Therapeutic Areas